Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OTC Head Ganley Talks Third Class, Plan B And Drug Switches

This article was originally published in The Tan Sheet

Executive Summary

This spring, FDA's Division of OTC Drug Products will be elevated to full office status within the Center for Drug Evaluation & Research. OTC Division Director Charles Ganley, MD, sat down with "The Tan Sheet" on Dec. 17 to discuss the ramifications of the organizational change, as well as hot-button issues such as the current Rx-to-OTC switch environment, possible monograph system improvements and advisory committee reviews.
Advertisement

Related Content

Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins
Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins
Balance In OND Offices' Staffing Drives CDER Reorganization - Jenkins
FDA's ONP Reorganization Challenges Industry To Prioritize OTCs
FDA's ONP Reorganization Challenges Industry To Prioritize OTCs
FDA's ONP Reorganization Challenges Industry To Prioritize OTCs
ONP: Leaner, Meaner In 2006
Nonprescription Office In Transition Works To Hire Division Heads
FDA Decision Has Plan B Headed For Behind-The-Counter Sale
Woodcock’s Message To OTC Industry: Innovation, Innovation, Innovation

Topics

Advertisement
UsernamePublicRestriction

Register

PS097663

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel